New Horizons for the Use of Valsartan + Sacubitril in Heart Failure Patients with Hypertension
https://doi.org/10.18087/cardio.2025.11.n3041
Abstract
The growing burden of chronic heart failure (CHF) and arterial hypertension (AH) requires improved secondary prevention with the consideration of recent advances in drug therapy. Since 2015, angiotensin II receptor antagonists in combination with other drugs (valsartan + sacubitril) have been recommended for patients with CHF and reduced left ventricular ejection fraction (LVEF) due to the positive effect of these drugs on prognosis. Currently, the indications for the use of valsartan + sacubitril have been expanded to include not only essential AH but also CHF with any LVEF in order to improve survival and reduce the frequency of hospitalizations. This article discusses current advances in the combination therapy in multimorbid patients with CHF and AH to achieve target blood pressure and reduce the risk of cardiovascular complications when using these drugs, their advantages, efficacy, tolerability, and safety profile.
Keywords
Heart failure,
arterial hypertension,
neprilysin,
natriuretic peptides,
valsartan,
sacubitril,
angiotensin II receptor antagonists in combination with other drugs
Supporting agencies: No conflict of interest is reported.
About the Authors
V. N. Larina
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
MD, Dr. Sci. (Med.), Professor
Moscow, Russia
V. G. Larin
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
PhD, Associate Professor
Moscow, Russia
References
1. Chan DZL, Kerr AJ, Doughty RN. Temporal trends in the burden of heart failure. Internal Medicine Journal. 2021;51(8):1212–8. DOI: 10.1111/imj.15253
2. Shlyakhto E.V., Belenkov Yu.N., Boytsov S.A., Villevalde S.V., Galyavich A.S., Glezer M.G. et al. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation ‘PRIORITET-CHF’: initial characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023;28(10):93–103. DOI: 10.15829/1560-4071-2023-5593
3. Manolis AA, Manolis TA, Manolis AS. Neurohumoral Activation in Heart Failure. International Journal of Molecular Sciences. 2023;24(20):15472. DOI: 10.3390/ijms242015472
4. Gokhroo RK, Anushri K, Tarik MT, Kailash C, Rajesh N, Ashish K et al. 1 year follow Up results of “ARTIM HF TRIAL” (angiotensin receptor neprilysin inhibitor effect on TEI index & left ventricular mass in heart failure). Indian Heart Journal. 2021;73(2):205–10. DOI: 10.1016/j.ihj.2021.01.010
5. Zannad F, Ferreira JP. Is Sacubitril/Valsartan Antifibrotic? Journal of the American College of Cardiology. 2019;73(7):807–9. DOI: 10.1016/j.jacc.2018.11.041
6. Tantisuwat L, Saengklub N, Boonpala P, Kumphune S, Panyasing Y, Kalandakanond-Thongsong S et al. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation. Scientific Reports. 2023;13(1):11472. DOI: 10.1038/s41598-023-38694-6
7. In brief: Sacubitril/valsartan (Entresto) expanded indication. The Medical Letter on Drugs and Therapeutics. 2021;63(1623):65. PMID: 33976096
8. Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R et al. 2021 Annual Report of the National Poison Data System© (NPDS) from America’s Poison Centers: 39th Annual Report. Clinical Toxicology. 2022;60(12):1381–643. DOI: 10.1080/15563650.2022.2132768
9. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128
10. Mareev V.Yu., Fomin I.V., Ageev F.T., Arutiunov G.P., Begrambekova Yu.L., Belenkov Yu.N. et al. Clinical guidelines. Chronic heart failure (CHF). Russian Heart Failure Journal. 2017;18(1):3–40. DOI: 10.18087/rhfj.2017.1.2346
11. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageev F.T., Arutyunov G.P., Begrambekova Yu.L. et al. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311–74. DOI: 10.15829/1560-4071-2020-4083
12. Galyavich A.S., Tereshchenko S.N., Uskach T.M., Ageev F.T., Aronov D.M., Arutyunov G.P. et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):251–349. DOI: 10.15829/1560-4071-2024-6162
13. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin–niprilysin Inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014;371(11):993–1004. DOI: 10.1056/NEJMoa1409077
14. Packer M, McMurray JJV, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin receptor niprilysin Inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54–61. DOI: 10.1161/CIR-CULATIONAHA.114.013748
15. López‐Azor JC, Vicent L, Valero‐Masa MJ, Esteban‐Fernández A, Gómez‐Bueno M, Pérez Á et al. Safety of sacubitril/valsartan initiated during hospitalization: data from a non‐selected cohort. ESC Heart Failure. 2019;6(6):1161–6. DOI: 10.1002/ehf2.12527
16. Moliner-Abós C, Mojón Álvarez D, Rivas-Lasarte M, Belarte LC, Pamies Besora J, Solé-González E et al. A Simple Score to Identify Super-Responders to Sacubitril/Valsartan in Ambulatory Patients With Heart Failure. Frontiers in Physiology. 2021;12:642117. DOI: 10.3389/fphys.2021.642117
17. Pharithi RB, Ferre‐Vallverdu M, Maisel AS, O’Connell E, Walshe M, Sweeney C et al. Sacubitril‐Valsartan in a routine community population: attention to volume status critical to achieving target dose. ESC Heart Failure. 2020;7(1):159–67. DOI: 10.1002/ehf2.12547
18. Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M et al. Optimizing Foundational Therapies in Patients With HFrEF: How Do We Translate These Findings Into Clinical Care? JACC: Basic to Translational Science. 2022;7(5):504–17. DOI: 10.1016/j.jacbts.2021.10.018
19. Branca L, Sbolli M, Metra M, Fudim M. Heart failure with mid‐range ejection fraction: pro and cons of the new classification of Heart Failure by European Society of Cardiology guidelines. ESC Heart Failure. 2020;7(2):381–99. DOI: 10.1002/ehf2.12586
20. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2019;381(17):1609–20. DOI: 10.1056/NEJMoa1908655
21. Solomon SD, Vaduganathan M, L. Claggett B, Packer M, Zile M, Swedberg K et al. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. Circulation. 2020;141(5):352–61. DOI: 10.1161/CIRCULATIONAHA.119.044586
22. Hsieh H-L, Chen C-Y, Chen C-H, Hsu S-C, Huang W-C, Sue Y-M et al. Renal protective effect of sacubitril/valsartan in patients with heart failure. Scientific Reports. 2021;11(1):4593. DOI: 10.1038/s41598-021-84118-8
23. Xiang B, Zhang R, Wu X, Zhou X. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis. JAMA Network Open. 2022;5(9):e2231963. DOI: 10.1001/jamanetworkopen.2022.31963
24. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. The Lancet. 2012;380(9851):1387–95. DOI: 10.1016/S0140-6736(12)61227-6
25. Redfield MM, Borlaug BA. Heart Failure With Preserved Ejection Fraction: A Review. JAMA. 2023;329(10):827–38. DOI: 10.1001/jama.2023.2020
26. Jering KS, Zannad F, Claggett B, Mc Causland FR, Ferreira JP, Desai A et al. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. JACC: Heart Failure. 2021;9(1):13–24. DOI: 10.1016/j.jchf.2020.08.014
27. Vaduganathan M, Mentz RJ, Claggett BL, Miao ZM, Kulac IJ, Ward JH et al. Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF. European Heart Journal. 2023;44(31):2982–93. DOI: 10.1093/eurheartj/ehad344
28. Mc Causland FR, Vaduganathan M, Claggett B, Gori M, Jhund PS, McGrath MM et al. Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF Trial. JACC: Heart Failure. 2025;13(1):105–14. DOI: 10.1016/j.jchf.2024.08.022
29. Martin N, Manoharan K, Davies C, Lumbers RT. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction. Cochrane Database of Systematic Reviews. 2021;5(5):CD012721. DOI: 10.1002/14651858.CD012721.pub3
30. Stoicescu L, Crişan D, Morgovan C, Avram L, Ghibu S. Heart Fai lure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach. International Journal of Molecular Sciences. 2024;25(2):794. DOI: 10.3390/ijms25020794
31. Williams B, Cockcroft JR, Kario K, Zappe DH, Brunel PC, Wang Q et al. Effects of Sacubitril/Valsartan Versus Olmesartan on Central Hemodynamics in the Elderly With Systolic Hypertension: The PARAMETER Study. Hypertension. 2017;69(3):411–20. DOI: 10.1161/HYPERTENSIONAHA.116.08556
32. Sun Y, Yang H. Comparison of sacubitril/valsartan with olmesartan for hypertension: A meta-analysis of randomized controlled trials. Medicine. 2024;103(14):e37501. DOI: 10.1097/MD.0000000000037501
33. Kobalava Zh.D., Konradi A.O., Nedogoda S.V., Shlyakhto E.V., Arutyunov G.P., Baranova E.I. et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):230–329. DOI: 10.15829/1560-4071-2024-6117
34. Larina V.N., Rodyukova I.S., Kryzhanovsky S.M., Manko K.S., Timoshina E.V. Pharmacokinetics, Safety, and Bioequivalence Studies of Two-Components of Acrivario (Valsartan + Sacubitril) Versus Original Drug (Valsartan + Sacubitril) Tablets in Healthy Volunteers. Kardiologiia. 2025;65(10):68–73. DOI: 10.18087/cardio.2025.10.n3032
Review
For citations:
Larina V.N., Larin V.G. New Horizons for the Use of Valsartan + Sacubitril in Heart Failure Patients with Hypertension. Kardiologiia. 2025;65(11):112-120. (In Russ.) https://doi.org/10.18087/cardio.2025.11.n3041
Views:
210
JATS XML
Email this article 
Post a Comment 
